Publications by authors named "S van Wilpe"
Article Synopsis
- This study investigates the effectiveness and safety of a combination therapy using immune checkpoint inhibitors (ICIs) for certain subgroups of metastatic castration-resistant prostate cancer (mCRPC) patients who show an immunogenic profile.
- The trial involved 69 patients with specific genetic markers and assessed the disease control rate after treatment, aiming to exceed 22%.
- Results showed that 38% of patients achieved disease control beyond 6 months, with the highest success in patients with mismatch repair deficiency, but treatment led to significant side effects in some cases, with 20% permanently discontinuing therapy.
Purpose: Platinum-based chemotherapy and immune checkpoint inhibitors are key components of systemic treatment for muscle-invasive and advanced urothelial cancer. The ideal integration of these two treatment modalities remains unclear as clinical trials have led to inconsistent results. Modulation of the tumor-immune microenvironment by chemotherapy is poorly characterized.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors (ICIs) are effective for some metastatic urothelial cancer (mUC) patients, but only 20-25% see a durable response.
- A study investigated the potential of measuring circulating tumor DNA (ctDNA) levels during treatment to predict responsiveness to ICIs in mUC patients, using a discovery cohort of 40 and a validation cohort of 16.
- Results showed that increases in ctDNA at 3 and 6 weeks were strongly associated with shorter progression-free survival and overall survival, indicating that early ctDNA changes could guide better management of treatment strategies.
Article Synopsis
- Early detection of tumors in cancer patients leads to better treatment outcomes for less advanced cancers.
- Tumor-educated platelets (TEPs) can be used for cancer detection via RNA-based blood tests, identifying 18 different cancer types with high accuracy.
- The thromboSeq test showed 99% specificity in asymptomatic controls, accurately detecting two-thirds of cancers in advanced stages, and helped determine the origin of tumors in over 80% of cases.
Homologous recombination repair deficiency (HRD) is observed in 10% of patients with castrate-resistant prostate cancer (PCa). Preliminary data suggest that HRD-PCa might be more responsive to immune checkpoint inhibitors (ICIs). In this study, we compare the tumor immune landscape and peripheral T cell receptor (TCR) repertoire of patients with and without HRD-PCa to gain further insight into the immunogenicity of HRD-PCa.
View Article and Find Full Text PDF